SIMCERE PHARMACEUTICAL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.82 HKD | +0.34% |
|
+2.11% | -13.52% |
| Apr. 25 | Simcere Pharmaceutical’ Profit Down 23% in 2023 | MT |
| Apr. 10 | Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA | MT |
ETFs positioned on Simcere Pharmaceutical Group Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.22% | 4 M€ | -27.92% | ||
| 0.24% | 2 M€ | -14.14% | ||
| 0.01% | 0 M€ | +3.95% | - | |
| 0.00% | 0 M€ | +4.81% | - | |
| 0.00% | 0 M€ | +3.63% | - |
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.382
CNY
Average target price
7.984
CNY
Spread / Average Target
+48.35%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.52% | 1.91B | |
| +19.62% | 43.27B | |
| +24.52% | 22.92B | |
| +20.29% | 15.43B | |
| +7.48% | 12.95B | |
| +42.51% | 11.83B | |
| -8.84% | 6.91B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.13% | 5.55B |
- Stock Market
- Equities
- 2096 Stock
- Funds and ETFs Simcere Pharmaceutical Group Limited
